Universal Beteiligungs und Servicegesellschaft mbH Decreases Stake in RadNet, Inc. $RDNT

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in RadNet by 62.4%, selling 34,327 shares in Q4 and now holds 20,677 shares valued at about $1.48 million.
• Wall Street consensus rates RadNet a Moderate Buy with a consensus price target of $88.14, despite mixed analyst actions (Jefferies $91 target, Barclays cut to $70; two Strong Buy, six Buy, one Hold, one Sell).
• RadNet beat Q expectations with EPS of $0.23 vs. $0.19 and revenue of $547.7M (up 14.8% year-over-year), although it still posts a slight negative net margin (~0.9%); the stock trades near $56.85 with a 12‑month range of $50.76–$85.84.

Universal Beteiligungs und Servicegesellschaft mbH lessened its stake in RadNet, Inc. (NASDAQ:RDNT - Free Report) by 62.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 20,677 shares of the medical research company's stock after selling 34,327 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH's holdings in RadNet were worth $1,476,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in RDNT. Allworth Financial LP boosted its stake in shares of RadNet by 346.6% in the 3rd quarter. Allworth Financial LP now owns 393 shares of the medical research company's stock valued at $30,000 after buying an additional 305 shares during the period. Danske Bank A S purchased a new stake in RadNet during the third quarter worth approximately $30,000. Farther Finance Advisors LLC lifted its stake in RadNet by 1,086.5% during the third quarter. Farther Finance Advisors LLC now owns 439 shares of the medical research company's stock worth $33,000 after purchasing an additional 402 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in RadNet by 62.2% during the third quarter. Jones Financial Companies Lllp now owns 446 shares of the medical research company's stock worth $34,000 after purchasing an additional 171 shares during the last quarter. Finally, Salomon & Ludwin LLC purchased a new stake in RadNet during the third quarter worth approximately $37,000. Hedge funds and other institutional investors own 77.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Jefferies Financial Group restated a "buy" rating and set a $91.00 target price on shares of RadNet in a research note on Tuesday, March 3rd. Barclays decreased their target price on RadNet from $86.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, April 21st. KeyCorp upgraded RadNet to a "strong-buy" rating in a research note on Friday, January 9th. Finally, UBS Group set a $92.00 target price on RadNet in a research note on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, RadNet has a consensus rating of "Moderate Buy" and a consensus price target of $88.14.

RadNet Trading Up 0.5%

NASDAQ:RDNT opened at $56.85 on Friday. The firm has a market cap of $4.45 billion, a P/E ratio of -227.40 and a beta of 1.44. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.79. The stock's 50 day simple moving average is $60.89 and its 200-day simple moving average is $70.23. RadNet, Inc. has a 12-month low of $50.76 and a 12-month high of $85.84.

RadNet (NASDAQ:RDNT - Get Free Report) last released its earnings results on Monday, March 2nd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.04. The business had revenue of $547.71 million for the quarter, compared to analyst estimates of $515.67 million. RadNet had a positive return on equity of 2.52% and a negative net margin of 0.91%.The company's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 earnings per share. Equities analysts anticipate that RadNet, Inc. will post 0.64 EPS for the current year.

Insider Activity

In other news, insider Alma Gregory Sorensen sold 15,000 shares of the business's stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $62.15, for a total value of $932,250.00. Following the transaction, the insider owned 1,208,923 shares of the company's stock, valued at approximately $75,134,564.45. The trade was a 1.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.60% of the company's stock.

About RadNet

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.